Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma

LESSONS LEARNED: Trials dedicated to metastatic uveal melanoma are needed because of the poor prognosis of this rare cancer and because its biology is distinct from that of cutaneous melanoma. Agents targeting the MEK/ERK/MAP kinase pathways are being tested. BACKGROUND. In experimental models, beva...

Descripción completa

Detalles Bibliográficos
Autores principales: Piperno-Neumann, Sophie, Diallo, Alhassane, Etienne-Grimaldi, Marie-Christine, Bidard, François-Clément, Rodrigues, Manuel, Plancher, Corine, Mariani, Pascale, Cassoux, Nathalie, Decaudin, Didier, Asselain, Bernard, Servois, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786360/
https://www.ncbi.nlm.nih.gov/pubmed/26911405
http://dx.doi.org/10.1634/theoncologist.2015-0501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786360/
https://www.ncbi.nlm.nih.gov/pubmed/26911405
http://dx.doi.org/10.1634/theoncologist.2015-0501

Ejemplares similares